Fungiscope - Global Emerging Fungal Infection Registry

Global Emerging Fungal Infection Registry

Lupe

Associates

Chair
Prof. Oliver A. Cornely MD,
FACP, FIDSA, FAAM, FECMM, Cologne

Scientific Lead
Dr. Danila Seidel PhD,
Cologne

Project Manager
Natalia Vasenda MSc,
Cologne

Coordinating Physicians and Quality Control Team Cologne
Dr. Philipp Köhler MD
Dr. Jon Salmanton-García PhD
Dr. Rosanne Sprute MD
Dr. Jannik Stemler MD
Dr. Sibylle Mellinghoff MD
Stefanie Gräfe MD
Andrea Will

Epidemiology, IT & Statistics
Prof. J. Janne Vehreschild MD, FECMM, Cologne

Microbiology and Sample Storage
Dr. Hilmar Wisplinghoff MD,
Cologne

Molecular Identification
Dr. Volker Rickerts MD,
Berlin

Histopathology
Dr. Birgid Markiefka MD,
Cologne

Thoracic Surgery
Prof. Khosro Hekmat MD,
Cologne

Therapeutic Drug Monitoring
Dr. Carsten Müller MD,
Cologne

NEWS

See here our latest FungiScope Newsletter

Also check out the ID Week Poster about the FURI Study



The Russian invasion of Ukraine is an attack on our most basic values of freedom and democracy. Our full solidarity goes out to the Ukrainian people.


Dear FungiScope Partners,

FungiScope declares solidarity with Ukraine.

FungiScope and its partners strongly condemn Russia´s attack on Ukraine in violation of international law. The Russian invasion of Ukraine is an incredible assault on the pillars of our society: freedom, democracy, self-determination and integrity.

Our full solidarity goes out to the Ukranian people and all those who courageously fight for a better future in Russia regardless of the individual consequences while trying.

It is with deep regrets that we close all FungiScope sites in Russia and Belarus.


Introduction

Prof. Oliver A. Cornely: A brief introduction to FungiScope


Objectives


The incidence of invasive fungal infections is increasing worldwide. While the etiology of this development has not been completely understood, evermore invasive medical care as well as increasing numbers of long-term immunocompromised patients are considered major contributing factors.
To counter this development, diagnostic and therapeutic standards have been established for the most common fungi, i.e. Candida spp., Aspergillus spp., Cryptococcus spp. and Pneumocystis jirovecii.
However, a wide variety of so-called emerging fungi accounts for a significant proportion of invasive fungal infections. Data on their epidemiology, pathogen biology and clinical course is scarce, often impeding evidence-guided decision making in the clinical setting.

To overcome these difficulties and eventually improve patient care, FungiScope — Global Registry for Emerging Fungal Infections has been created in 2003. As of August 2018, 899 retrospective cases have been entered.


Methods


FungiScope follows a multi-modal approach, including the following components:

  • Filing retrospective, anonymized patient data in an online database, to register please contact us
  • FungiThek: Biobanking and reference analysis of fungal isolates
  • Epidemiological survey on the incidences of emerging fungal infections
  • Clinicians´ search engine of the FungiScope database: FungiQuest
  • Therapeutic antifungal drug monitoring for participating centers
  • Providing specimens to cooperating centers for defined research projects. Prior to sharing of samples or data, approval of the contributors of the respective cases will be obtained.
  • Statistical analysis based on FungiScope data only, or in cooperation with other centers/registries

The registry is open to everybody who encounters a case of a rare or emerging fungal infection in their clinical work and wishes to contribute the case to FungiScope. Please contact us to receive your personal FungiScope account details to access the online case report form.


Authorship Policy


Together, we publish subsets of this cohort. Authorship is restricted to those centers contributing cases or translational work or specimens to the subset published. For each contributing center there will be authorship positions available.

A working group of the

ECMM
ISHAM

in cooperation with

MSG
DMYKG CEll
AGIHO
NRZMyk
dgi
EFISG
PEG
SRMMM ÖGMM
fimua

listed at

orphanet
R4R

ClinicalTrials.gov Identifier: NCT01731353

Supported by unrestricted grants from
Amplyx Pharmaceuticals,
Basilea Pharmaceutica,
Cidara Therapeutics,
F2G Ltd., Pfizer Inc., and SCYNEXIS Inc.